Genomic Surveillance of SARS-CoV-2 Variants at a Reference Cancer Hospital in Rio de Janeiro, Brazil

Introduction: The fast SARS-CoV-2 spread and high mutation rates during viral replication led to virus diversification and the emergence of new variants. Genomic surveillance has been key to monitoring SARS-CoV-2 variants across the globe. Immune suppression, as observed in cancer patients, is a ris...

Descripción completa

Detalles Bibliográficos
Autores: Oliveira, Élida Mendes de, Sá, Caroline Carvalho de, Cordeiro, Julia Botto de Barros, Thuler, Luiz Claudio Santos, Assumpção, Maria Eduarda Lanzillota, Andrade, Gabriela Seara de, Vizzoni, Vinicius Figueiredo, Viola, João Paulo de Biaso, Soares, Marcelo Alves, Siqueira, Juliana Domett, Goes, Livia Ramos
Tipo de recurso: artículo
Estado:Versión publicada
Fecha de publicación:2024
País:Brasil
Institución:Instituto Nacional de Câncer José Alencar Gomes da Silva (INCA)
Repositorio:Revista Brasileira de Cancerologia (Online)
Idioma:inglés
OAI Identifier:oai:rbc.inca.gov.br:article/4637
Acceso en línea:https://rbc.inca.gov.br/index.php/revista/article/view/4637
Access Level:acceso abierto
Palabra clave:SARS-CoV-2
COVID-19
Neoplasias/genética
Epidemiological Monitoring
Genoma Viral
Neoplasms/genetics
Genome, Viral
Monitoreo Epidemiológico
Descripción
Sumario:Introduction: The fast SARS-CoV-2 spread and high mutation rates during viral replication led to virus diversification and the emergence of new variants. Genomic surveillance has been key to monitoring SARS-CoV-2 variants across the globe. Immune suppression, as observed in cancer patients, is a risk factor for SARS-CoV-2 infection and severe COVID-19. Objective: To report a two-year genomic surveillance of SARS-CoV-2 in cancer patients followed up at the Brazilian National Cancer Institute, Rio de Janeiro, Brazil. Method: Prospective observational study with 384 SARS-CoV-2+ swabs specimens collected and evaluated between October 2020 and September 2022. SARS-CoV-2 spike was analyzed by PCR and Sanger sequencing to determine the infecting variant. Results: Most of the patients had solid organ malignancies (298/384; 77.6%) and 16.1% (62/384) had metastatic disease. Severe COVID-19 cases accounted for 29.4% (113/384) and 27.1% (104/384) of deaths registered. The most common SARS-CoV-2 infecting variants were Gamma (n=137) and Omicron (BA.1) (n=73). The variant distribution overtime was similar to what has been reported for the general population of Brazil in the same period. When patients’ cancer topographies were analyzed, it was found that Gamma infected patients with breast (47/137; 34.3%) and cervical (11/137; 8%) cancer were more frequent than other variants, while Omicron predominated among rectum (10/122; 8.2%) and prostate (8/122; 6.6%) cancer compared to other variants. Conclusion: Genomic surveillance is an important tool for identifying and evaluating the impact of SARS-CoV-2 variants, and should continue especially in immunosuppressed populations.